loading
Senti Biosciences Inc stock is traded at $2.11, with a volume of 98,809. It is up +2.93% in the last 24 hours and down -34.06% over the past month. Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$2.05
Open:
$2.03
24h Volume:
98,809
Relative Volume:
0.61
Market Cap:
$78.77M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.1358
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
-7.46%
1M Performance:
-34.06%
6M Performance:
-49.03%
1Y Performance:
-31.34%
1-Day Range:
Value
$1.98
$2.22
1-Week Range:
Value
$1.90
$2.315
52-Week Range:
Value
$1.5201
$16.94

Senti Biosciences Inc Stock (SNTI) Company Profile

Name
Name
Senti Biosciences Inc
Name
Phone
(650) 382-3281
Name
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Name
Employee
48
Name
Twitter
Name
Next Earnings Date
2024-08-16
Name
Latest SEC Filings
Name
SNTI's Discussions on Twitter

Compare SNTI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SNTI
Senti Biosciences Inc
2.11 78.77M 1.79M -70.90M -34.95M -15.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Laidlaw Buy
Oct-07-22 Initiated Morgan Stanley Equal-Weight

Senti Biosciences Inc Stock (SNTI) Latest News

pulisher
Jun 18, 2025

Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 09, 2025

Senti Biosciences Announces New Employment Inducement Grants - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan

Jun 09, 2025
pulisher
Jun 08, 2025

Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 07, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News

Jun 07, 2025
pulisher
Jun 07, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com

Jun 06, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
May 30, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com

May 29, 2025
pulisher
May 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire

May 26, 2025
pulisher
May 25, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 23, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times

May 23, 2025
pulisher
May 22, 2025

Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com

May 20, 2025
pulisher
May 16, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 16, 2025
pulisher
May 09, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com

May 08, 2025
pulisher
May 08, 2025

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World

May 07, 2025
pulisher
May 07, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent

May 05, 2025

Senti Biosciences Inc Stock (SNTI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Senti Biosciences Inc Stock (SNTI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lu Timothy K
CEO
Feb 06 '25
Sale
4.36
545
2,376
82,082
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 04 '25
Sale
4.07
1,297
5,279
8,803
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 06 '25
Sale
4.37
182
795
8,621
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):